 Pancreatic Neoplasms
"Pancreatic Neoplasms" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Tumors or cancer of the PANCREAS. Depending on the types of ISLET CELLS present in the tumors, various hormones can be secreted: GLUCAGON from PANCREATIC ALPHA CELLS; INSULIN from PANCREATIC BETA CELLS; and SOMATOSTATIN from the SOMATOSTATIN-SECRETING CELLS. Most are malignant except the insulin-producing tumors (INSULINOMA).
| Descriptor ID |
D010190
|
| MeSH Number(s) |
C04.588.274.761 C04.588.322.421 C06.301.761 C06.689.667 C19.344.421
|
| Concept/Terms |
Pancreatic Neoplasms- Pancreatic Neoplasms
- Neoplasm, Pancreatic
- Pancreatic Neoplasm
- Neoplasms, Pancreatic
- Pancreas Neoplasms
- Neoplasm, Pancreas
- Neoplasms, Pancreas
- Pancreas Neoplasm
Cancer of Pancreas- Cancer of Pancreas
- Pancreas Cancers
- Pancreas Cancer
- Cancer, Pancreas
- Cancers, Pancreas
- Pancreatic Cancer
- Cancer, Pancreatic
- Cancers, Pancreatic
- Pancreatic Cancers
- Cancer of the Pancreas
|
Below are MeSH descriptors whose meaning is more general than "Pancreatic Neoplasms".
Below are MeSH descriptors whose meaning is more specific than "Pancreatic Neoplasms".
This graph shows the total number of publications written about "Pancreatic Neoplasms" by people in this website by year, and whether "Pancreatic Neoplasms" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1981 | 3 | 0 | 3 | | 1982 | 0 | 2 | 2 | | 1983 | 6 | 0 | 6 | | 1984 | 3 | 0 | 3 | | 1985 | 2 | 0 | 2 | | 1986 | 4 | 0 | 4 | | 1987 | 1 | 4 | 5 | | 1988 | 1 | 0 | 1 | | 1989 | 1 | 0 | 1 | | 1990 | 3 | 0 | 3 | | 1991 | 1 | 0 | 1 | | 1992 | 6 | 1 | 7 | | 1993 | 4 | 0 | 4 | | 1994 | 9 | 4 | 13 | | 1995 | 5 | 2 | 7 | | 1996 | 2 | 0 | 2 | | 1997 | 2 | 1 | 3 | | 1998 | 2 | 1 | 3 | | 1999 | 5 | 1 | 6 | | 2000 | 2 | 1 | 3 | | 2001 | 5 | 0 | 5 | | 2002 | 8 | 8 | 16 | | 2003 | 3 | 1 | 4 | | 2004 | 7 | 2 | 9 | | 2005 | 23 | 3 | 26 | | 2006 | 14 | 3 | 17 | | 2007 | 20 | 3 | 23 | | 2008 | 19 | 3 | 22 | | 2009 | 23 | 3 | 26 | | 2010 | 25 | 2 | 27 | | 2011 | 20 | 4 | 24 | | 2012 | 11 | 2 | 13 | | 2013 | 23 | 3 | 26 | | 2014 | 24 | 1 | 25 | | 2015 | 18 | 2 | 20 | | 2016 | 36 | 2 | 38 | | 2017 | 24 | 4 | 28 | | 2018 | 22 | 2 | 24 | | 2019 | 30 | 3 | 33 | | 2020 | 8 | 2 | 10 | | 2021 | 1 | 0 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Pancreatic Neoplasms" by people in Profiles.
-
Sachs TE, Tseng JF. Landmark Series in Pancreatic Tumors: Anastomotic Techniques and Route of Reconstruction. Ann Surg Oncol. 2021 Apr; 28(4):2227-2234.
-
Blanco BA, Poulson M, Kenzik KM, McAneny DB, Tseng JF, Sachs TE. The Impact of Residential Segregation on Pancreatic Cancer Diagnosis, Treatment, and Mortality. Ann Surg Oncol. 2021 Jun; 28(6):3147-3155.
-
Schuster B, Junkin M, Kashaf SS, Romero-Calvo I, Kirby K, Matthews J, Weber CR, Rzhetsky A, White KP, Tay S. Automated microfluidic platform for dynamic and combinatorial drug screening of tumor organoids. Nat Commun. 2020 10 19; 11(1):5271.
-
Liu D, Zhou D, Sun Y, Zhu J, Ghoneim D, Wu C, Yao Q, Gamazon ER, Cox NJ, Wu L. A Transcriptome-Wide Association Study Identifies Candidate Susceptibility Genes for Pancreatic Cancer Risk. Cancer Res. 2020 10 15; 80(20):4346-4354.
-
Gajewski TF, Cron KR. cDC1 dysregulation in cancer: An opportunity for intervention. J Exp Med. 2020 08 03; 217(8).
-
Vining CC, Kuchta K, Schuitevoerder D, Paterakos P, Berger Y, Roggin KK, Talamonti MS, Hogg ME. Risk factors for complications in patients undergoing pancreaticoduodenectomy: A NSQIP analysis with propensity score matching. J Surg Oncol. 2020 Aug; 122(2):183-194.
-
Vaghaiwalla T, Ruhle B, Memeh K, Angelos P, Kaplan E, Liao CY, Polite B, Keutgen X. Response rates in metastatic neuroendocrine tumors receiving peptide receptor radionuclide therapy and implications for future treatment strategies. Surgery. 2021 01; 169(1):162-167.
-
Kupfer SS, Gupta S, Weitzel JN, Samadder J. AGA Clinical Practice Update on Colorectal and Pancreatic Cancer Risk and Screening in BRCA1 and BRCA2 Carriers: Commentary. Gastroenterology. 2020 08; 159(2):760-764.
-
Golan T, Kindler HL, Park JO, Reni M, Macarulla T, Hammel P, Van Cutsem E, Arnold D, Hochhauser D, McGuinness D, Locker GY, Goranova T, Schatz P, Liu YZ, Hall MJ. Geographic and Ethnic Heterogeneity of Germline BRCA1 or BRCA2 Mutation Prevalence Among Patients With Metastatic Pancreatic Cancer Screened for Entry Into the POLO Trial. J Clin Oncol. 2020 05 01; 38(13):1442-1454.
-
O'Reilly EM, Lee JW, Zalupski M, Capanu M, Park J, Golan T, Tahover E, Lowery MA, Chou JF, Sahai V, Brenner R, Kindler HL, Yu KH, Zervoudakis A, Vemuri S, Stadler ZK, Do RKG, Dhani N, Chen AP, Kelsen DP. Randomized, Multicenter, Phase II Trial of Gemcitabine and Cisplatin With or Without Veliparib in Patients With Pancreas Adenocarcinoma and a Germline BRCA/PALB2 Mutation. J Clin Oncol. 2020 05 01; 38(13):1378-1388.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|